OICHARTS
8 AMThe 8 AM report →

BMRN

BioMarin Pharmaceuticals Inc · XNAS · 131 sessions on record
$60.00▲ +0.13 · +0.2%from $59.87 the session before · Sep 30, 2026 close · end of day
Open
$59.90
High
$60.71
Low
$59.37
Day's range
$1.32.2% of the previous close
VWAP
$60.16close −0.27% from it
Volume, shares
1.8M0.90× the 20-session average
Traded, $
$108.2M
Trades
24.4K74 shares per trade
Previous close
$59.87+0.13 to the close
Market cap
$11.61Bat the close of Sep 30
Day range47% of the way up
$59.37$60.71
52-week range49% of the way up
$49.26 May 18$70.98 Aug 12

−15% from the high · +22% from the low

Options

No listed options on BMRN

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close
131 sessions on file · from Mar 25
BMRN close over the last 126 sessions, with S&P 500 rebased to the first close49.6759.9570.24axis spans 41%S&P 500BMRNApr 1Jul 2Sep 30126 sessions from Apr 1 to Sep 30; the price axis spans 41 percent.

Quarterly results

consolidated · latest filed Aug 6, 2026 · SEC filings

Revenue $989.7M, +20% on a year earlier; profit $44.8M, −81% in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of BMRN on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue $Revenue YoYProfit $Profit YoYEPS $Market on the day
Jun 2026filed Aug 6$989.7M▲ +20%$44.8M▼ −81%0.23▲ +3.8%S&P 500 +0.6% · +3.2 pp
Mar 2026filed May 5$766.2M▲ +2.8%$105.5M▼ −43%0.54▲ +2.6%S&P 500 +1.4% · +1.2 pp
Dec 2025filed Feb 26$874.6M▲ +17%−$46.6M▼ −140%-0.22—not reached
Sep 2025filed Oct 28$776.1M▲ +4.1%−$30.7M▼ −130%-0.16—not reached
Jun 2025filed Aug 6$825.4M▲ +16%$240.5M▲ +120%1.23▲ +3.8%S&P 500 +0.6% · +3.2 pp
Mar 2025filed May 5$745.1M▲ +15%$185.7M▲ +110%0.95▲ +2.6%S&P 500 +1.4% · +1.2 pp
Dec 2024filed Feb 24$747.3M▲ +16%$124.9M▲ +510%0.65—not reached
Sep 2024filed Oct 28$745.7M▲ +28%$106.1M▲ +160%0.55—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of BMRN on the consolidated basis, summed from the quarters filed
YearRevenue $Revenue YoYProfit $Profit YoYEPS $
FY25to Dec 2025$3.22B▲ +13%$348.9M▼ −18%1.80
FY24to Dec 2024$2.85B▲ +18%$426.9M▲ +150%2.21
FY23to Dec 2023$2.42B▲ +15%$167.6M▲ +18%0.87
FY22to Dec 2022$2.10B▲ +14%$141.6M—0.75
FY21to Dec 2021$1.85B▼ −0.76%−$64.1M▼ −110%-0.35

Fundamentals

consolidated · filings to Jun 2026 · close $60.00 on Sep 30

BMRN trades at 150 times trailing earnings against 20 for its industry, 1.8 times book value, revenue +11% over twelve months, market cap $11.61B.

Valuation
Market cap
$11.61Bon Sep 30
Price to earnings
150consolidated · four quarters to Jun 2026 · industry 20
Trailing EPS
$0.39diluted · consolidated · four quarters to Jun 2026
Price to book
1.8consolidated · balance sheet to Jun 2026
Book value a share
$32.66consolidated · balance sheet to Jun 2026
Debt to equity
0.66borrowings over equity · consolidated · balance sheet to Jun 2026
Return on equity
1.2%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
3.4market cap over revenue, four quarters to Jun 2026
Shares outstanding
194Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
$3.41Bfour quarters to Jun 2026
Revenue growth, 12 months
▲ +11%against the twelve months before
Revenue 3-year CAGR
▲ +15%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
$73.0Mfour quarters to Jun 2026
Profit growth, 12 months
▼ −89%against the twelve months before
Profit 3-year CAGR
▼ −10%trailing twelve months against the twelve months 3 years earlier · consolidated
PeersPharmaceutical Preparations · the ten largest by market cap · industry P/E 20, market caps over trailing profit of 6 stocks
Stocks in the industry Pharmaceutical Preparations with market cap, price to earnings and price to book
StockMarket capP/EP/BClose $
REGNRegeneron Pharmaceuticals Inc$71.24Bon Sep 3019consolidated2.3$758.27
UTHRUnited Therapeutics Corp$23.24Bon Sep 3019consolidated3.6$541.89
RPRXRoyalty Pharma plc Class A Ordinary Shares$22.65Bon Sep 3031consolidated—$58.36
BMRNBioMarin Pharmaceuticals Inc$11.61Bon Sep 30150consolidated1.8$60.00
LQDALiquidia Corporation Common Stock$2.71Bon Sep 3022consolidated14$30.26
ANIPANI Pharmaceuticals, Inc.$1.77Bon Sep 3016consolidated3.0$72.65
STOKStoke Therapeutics, Inc. Common Stock$1.68Bon Sep 30—4.9$26.00
MLTXMoonLake Immunotherapeutics Class A Ordinary Shares$995.7Mon Sep 30—2.3$11.70
JBIOJade Biosciences, Inc. Common Stock$893.5Mon Sep 301.7consolidated2.0$14.05
CLYMClimb Bio, Inc. Common Stock$658.8Mon Sep 30—2.8$11.47

Shareholding

quarter to Jun 2026 · SEC Form 13F

13F managers hold 200% of shares, BlackRock, Inc. the largest at 21%, Dodge & Cox 15% and PRIMECAP MANAGEMENT CO/CA/ 15%, as filed for the quarter to Jun 2026.

Held by 13F managers
200%of shares outstanding
Shares held
383M+1.6% on Mar 2026 among managers filing both
Managers holding
522519 a quarter earlier
Largest holder
21%BlackRock, Inc.
Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter
Largest 13F holders of BMRN
ManagerSharesOf outstandingValueChange on quarter
BlackRock, Inc.40.9M21%$2.34B+1.25M
Dodge & Cox29.7M15%$1.70B+566K
PRIMECAP MANAGEMENT CO/CA/28.4M15%$1.62B−7.64K
VANGUARD CAPITAL MANAGEMENT LLC17.5M9.0%$1.00B+201K
VANGUARD PORTFOLIO MANAGEMENT LLC17.3M8.9%$989.8M+700K
NORGES BANK16.4M8.5%$939.3M—
STATE STREET CORP15.6M8.1%$892.7M+1.01M
VIKING GLOBAL INVESTORS LP15.2M7.9%$871.6M+1.11M
Vestal Point Capital, LP12.1M6.2%$689.5M+4.9M
AQR CAPITAL MANAGEMENT LLC11.4M5.9%$645.1M−3.95M
Insider tradesSEC Forms 3, 4 and 5 · the latest 10

No open-market insider buying or selling in the last 90 days.

BMRN insider trades
InsiderTradeSharesPriceHeld after
ANDERSON ELIZABETH MDirectorgranted · Jun 2, 20267,490$0.0041,940
Bodem Barbara W.Directorgranted · Jun 2, 20267,490$0.0021,045
CLARK IAN TDirectorgranted · Jun 2, 20267,490$0.0014,490
Dere Willard HDirectorgranted · Jun 2, 20267,490$0.0046,440
Enyedy Mark JDirectorgranted · Jun 2, 20267,490$0.0021,040
HOMBACH ROBERT J.Directorgranted · Jun 2, 20267,490$0.0049,360
Ho MaykinDirectorgranted · Jun 2, 20267,490$0.0035,500
Walbert Timothy PDirectorgranted · Jun 2, 20267,490$0.0017,270
Countouriotis AthenaDirectorgranted · Jun 2, 20267,490$0.0021,040
Hubbard CristinOfficerwithheld for tax · May 20, 20262,318$50.2042,472

Corporate actions

exchange records

No corporate action on record for BMRN yet.

Price history

131 sessions on record · to Sep 30 · end of day

BMRN is −7.5% over 20 sessions against the S&P 500's +0.1%, 15% below its 52-week high, realised volatility 25% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
WindowFrom $BMRN %S&P 500 %Difference pp
120 sessionssince Apr 9$56.30▲ +6.6%▲ +12%−5.6
60 sessionssince Jul 7$60.35▼ −0.58%▲ +2.0%−2.6
20 sessionssince Sep 1$64.84▼ −7.5%▲ +0.11%−7.6
5 sessionssince Sep 23$62.21▼ −3.5%▼ −0.67%−2.9
1 sessionsince Sep 29$59.87▲ +0.22%▼ −0.21%+0.43
Averages of the closeclose against each average
5-session average
$60.19close −0.32% from it
20-session average
$63.77close −5.9% from it
50-session average
$64.02close −6.3% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$1.52.5% of the close
Average day's range, 20
$1.42.4% of the close
Volume against 20 sessions
0.90×1.8M vs 2.01M average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
25%≈ ±1.5% a session · moved more than that on 7 of 20
Realised volatility, 60
29%≈ ±1.8% a session · moved more than that on 11 of 60
Beta to S&P 500, 60
0.33moved with S&P 500 on 35 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
10 up · 10 downof 20
Last 60 sessions
29 up · 31 downof 60
Best session, 250
▲ +8.6%May 29
Worst session, 250
▼ −4.1%May 18

1 headlines on BMRN

latest Sep 25, 2026 · links go to the publisher
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS InsiderGlobeNewswire Inc.

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 61% of reported volume on Sep 30, 2026, against 54% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume
BMRN daily short-sale volume
SessionShort volumeReported volumeShort share
Sep 30, 2026333K549K60.6%
Sep 29, 2026389K691K56.2%
Sep 28, 2026420K908K46.2%
Sep 25, 2026165K560K29.4%
Sep 24, 2026210K480K43.7%
Sep 23, 2026432K935K46.2%
Sep 22, 2026385K935K41.2%
Sep 21, 2026239K654K36.5%
Sep 18, 2026313K541K57.8%
Sep 17, 2026334K482K69.4%

Filings

SEC EDGAR · newest first
BMRN SEC filings
FiledFormReport date
Sep 30, 20268-KSep 24, 2026
Sep 15, 20268-KSep 15, 2026
Sep 14, 20264Sep 10, 2026
Sep 14, 20263Sep 10, 2026
Sep 14, 20268-KSep 10, 2026
Sep 3, 20264Sep 2, 2026
Sep 2, 2026144—
Sep 1, 20268-KAug 31, 2026
Aug 31, 20268-KAug 30, 2026
Aug 18, 20268-KAug 17, 2026
Aug 6, 2026S-8—
Aug 6, 202610-QJun 30, 2026
Aug 6, 20268-KAug 6, 2026
Jul 13, 20268-K/AApr 27, 2026
Jun 4, 20264Jun 2, 2026
Jun 4, 20264Jun 2, 2026
Jun 4, 20264Jun 2, 2026
Jun 4, 20264Jun 2, 2026
Jun 4, 20264Jun 2, 2026
Jun 4, 20264Jun 2, 2026
Jun 4, 20264Jun 2, 2026
Jun 4, 20264Jun 2, 2026
Jun 4, 20264Jun 2, 2026
Jun 4, 20268-KJun 2, 2026
May 21, 20264May 20, 2026

About BioMarin Pharmaceuticals Inc

SEC and exchange records
Company
BioMarin Pharmaceuticals Inc
Exchange
XNAS
Industry
Pharmaceutical Preparations · SEC standard industrial classification
SEC CIK
1048477
Sessions on record
131
Price source
End of day · delayed
Computed
1 Oct, 10:41 pm IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.